Access cutting-edge advanced solid tumors treatment through this clinical trial at a research site in New Orleans. Study-provided care at no cost to qualified participants.
Access advanced solid tumors specialists in New Orleans at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate
Sponsor: Eli Lilly and Company
Check if you qualify for this advanced solid tumors clinical trial in New Orleans, LA
If you're searching for advanced solid tumors treatment options in New Orleans, LA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Orleans research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.